Treatment of osteogenesis imperfecta with the bisphosphonate olpadronate (dimethylaminohydroxypropylidene bisphosphonate)
EA Landsmeer-Beker, GG Massa… - European journal of …, 1997 - Springer
EA Landsmeer-Beker, GG Massa, PD Maaswinkel-Mooy, JJP Van De Kamp…
European journal of pediatrics, 1997•SpringerOsteoporosis is an important feature of osteogenesis imperfecta (OI). So far, no effective
medical treatment is available. We treated three boys with severe OI type III and vertebral
deformities for 5–7 years with continuous oral administration of the bisphosphonate,
olpadronate. Treatment resulted in a decreased number of bone fractures, an increased
calcification of the long bones and an amelioration of vertebral shape. No side-effects were
encountered. Conclusion These preliminary but long-term obser-vations suggest that the …
medical treatment is available. We treated three boys with severe OI type III and vertebral
deformities for 5–7 years with continuous oral administration of the bisphosphonate,
olpadronate. Treatment resulted in a decreased number of bone fractures, an increased
calcification of the long bones and an amelioration of vertebral shape. No side-effects were
encountered. Conclusion These preliminary but long-term obser-vations suggest that the …
Abstract
Osteoporosis is an important feature of osteogenesis imperfecta (OI). So far, no effective medical treatment is available. We treated three boys with severe OI type III and vertebral deformities for 5–7 years with continuous oral administration of the bisphosphonate, olpadronate. Treatment resulted in a decreased number of bone fractures, an increased calcification of the long bones and an amelioration of vertebral shape. No side-effects were encountered.
Conclusion These preliminary but long-term obser- vations suggest that the bisphosphonate olpadronate may be a useful treatment for patients with OI and vertebral fractures. Bisphosphonates may be promi- sing drugs for children with OI.
Springer
以上显示的是最相近的搜索结果。 查看全部搜索结果